Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. Review. PubMed PMID: 30482768; PubMed Central PMCID: PMC6258919.
Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27;2(22):3257-3291. doi: 10.1182/bloodadvances.2018024893. Review. PubMed PMID: 30482765; PubMed Central PMCID: PMC6258922.
Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018 Nov;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040. Epub 2018 Aug 22. PubMed PMID: 30144419.
Steffel J, Verhamme P, Potpara TS, et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136. PubMed PMID: 29562325.
Steffel J, Verhamme P, Potpara TS, et al. [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary]. Kardiol Pol. 2018;76(9):1283-1298. doi: 10.5603/KP.2018.0180. Polish. PubMed PMID: 30211938.
Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016 Oct;17(10):e452-e466. doi: 10.1016/S1470-2045(16)30369-2. Review. PubMed PMID: 27733271.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7. Erratum in: Chest. 2016 Oct;150(4):988. PubMed PMID: 26867832.Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013 Jul;34(27):2094-106. doi: 10.1093/eurheartj/eht134. Epub 2013 Apr 26. PubMed PMID: 23625209.
Both intravenous and subcutaneous unfractionated heparin (UFH) as well as subcutaneous low-molecular-weight heparins (LMWHs) are used.
1. Absolute contraindications:
1) Active clinically significant bleeding (in exceptional cases heparin may be considered in treatment of some forms of disseminated intravascular coagulation [DIC]).
2) Acute intracranial bleeding, spontaneous or posttraumatic subarachnoid hemorrhage (usually an anticoagulant may be started at prophylactic doses after 5-10 days, and at therapeutic doses after ≥2 weeks).
3) Uncontrolled congenital or acquired bleeding disorder.
4) Hypersensitivity to the drug.
5) A positive history of heparin-induced immune thrombocytopenia (HIT). In selected circumstances (eg, need for cardiac surgery), patients with prior HIT may be re-exposed to heparin if repeat HIT antibody testing is negative. Consultation with a hematologist is recommended.
2. Other clinical conditions associated with an increased risk of bleeding (relative contraindications): In these circumstances, the decision to use or not use anticoagulant therapy is based on an assessment of the risks versus the benefits of anticoagulation in individual patients.
1) Recent gastrointestinal (GI) bleeding or a GI condition associated with a high risk of bleeding.
2) Symptomatic portal hypertension.
3) Kidney failure: Creatinine clearance <30 mL/min (this applies to LMWHs and direct oral anticoagulants).
4) Severe liver failure.
5) Acute postinfarction pericarditis.
6) Uncontrolled hypertension: Systolic pressure >180 mm Hg or diastolic pressure >110 mm Hg.
7) Recent brain, spinal cord, or eye surgery (brain or spinal surgery, particularly in patients with additional risk factors for venous thromboembolism, is an indication for prophylaxis, often started as early as on the first day after surgery).
8) Brain tumor.
9) Diagnostic or therapeutic lumbar puncture.
10) ≤24 hours after surgery, organ biopsy, or artery puncture (up to 4 days in patients with abnormal hemostasis during surgery).
11) Aortic dissection.
12) Diabetic retinopathy.
The risk of bleeding is increased in patients simultaneously treated with antiplatelet and anticoagulant agents; however, such combination therapy may be indicated (eg, in acute coronary syndromes).
1. UFH: Measure the activated partial thromboplastin time (aPTT). In patients in whom the target aPTT cannot be achieved despite the use of high-dose UFH, measure anti-Xa activity and adjust the dose of UFH or switch from UFH to LMWH based on the results.
2. LMWH: It is not necessary to monitor the anticoagulant effect by measuring anti-Xa activity except for pregnant patients receiving therapeutic doses of LMWHs, patients with severe obesity (eg, >150 kg), and patients with creatinine clearance <30 mL/min; it may be considered in individuals with a history of a thromboembolic event or major bleeding in the course of LMWH treatment, particularly in the elderly. The anticoagulant effect (measured 4 hours after the administration of the drug) is considered satisfactory if anti-Xa levels are 0.6 to 1 U/mL in a patient receiving LMWH every 12 hours or 1 to 1.3 U/mL in a patient receiving LMWH every 24 hours.
Subcutaneous injections very frequently cause ecchymosis at the site of injection. Cases of life-threatening or health-threatening bleeding (most frequently GI, intracranial, or retroperitoneal) are rare; they require treatment to neutralize the anticoagulant effect of heparin.
1. Neutralization of the effects of UFH:
1) For every 100 U of UFH, administer 1 mg IV protamine (eg, for 5000 U of UFH, administer 50 mg of protamine). The injection should be slow (over 1-3 minutes) to avoid hypotension and bradycardia,
2) Due to the short half-life of UFH (60-90 minutes) when calculating the dose of protamine in patients receiving UFH by intravenous infusion take into account only the amount of UFH administered in the last 3 hours (eg, in a patient receiving an infusion of 1250 U/h, administer 40 mg of protamine).
3) Monitor the effects of treatment by measuring the aPTT (it should become shorter in the course of the treatment).
2. Neutralization of the effects of LMWHs: No established method exists. If the patient has received LMWH within the prior 8 hours, administer 1 mg of IV protamine for every 100 U of anti-Xa (eg, 1 mg of enoxaparin or 150 U of anti-Xa nadroparin); in patients who have received LMWH >8 hours before, use a lower dose (eg, 0.5 mg of protamine). If bleeding persists, you may administer an additional 0.5 mg of IV protamine for every 100 U of anti-Xa.
1. Types of HIT:
1) Non–immune-mediated (type I) HIT is usually associated with a mild reduction in the platelet counts (generally not falling <100,000/microL) observed in 10% to 20% of patients during the first 2 to 4 days of UFH treatment. This causes no clinical manifestations and the platelet count returns to normal despite continued treatment with heparin.
2) Immune-mediated (type II) HIT, usually referred to simply as HIT, involves a reduction in platelet counts by >50% (usually to 30,000-50,000/microL, although in 10% of patients platelet counts are >150,000/microL, and in 5% of patients [most often with DIC], <20,000/microL). It usually occurs after 4 to 10 days of UFH/LMWH treatment in 0.1% to 3% of patients receiving UFH (in <0.1% of those treated with LMWHs) and is associated with a 20-fold to 40-fold increase in the risk of venous or arterial thrombosis (not bleeding!), which develops in 30% to 75% of patients with HIT.
2. Risk of HIT and the need for monitoring platelet counts:
1) High risk (>1%): Patients after surgery receiving UFH at prophylactic or therapeutic doses for >4 days (particularly after cardiac, vascular, or orthopedic surgery) and patients with cancer. In these patients, monitor platelet counts at least every 2 to 3 days for the first 14 days of heparin treatment or until its discontinuation if the treatment lasts <14 days.
2) Moderate risk (0.1%-1%): Medical patients and pregnant women receiving UFH for >4 days; patients after surgery receiving LMWH for >4 days; patients after surgery or patients requiring intensive care in whom UFH is used to flush a central venous catheter; medical patients and pregnant women receiving LMWHs who have previously received at least one dose of UFH. In these groups monitor platelet counts at least every 2 to 3 days, from day 4 until day 14 of treatment, or until its discontinuation if lasting <14 days.
3) Low risk (<0.1%): All patients receiving UFH for <4 days; medical patients and pregnant women receiving LMWH regardless of the time since the start of the treatment, and medical patients in whom UFH is used to flush a central venous catheter. In these groups it is not necessary to monitor platelet counts.
When starting treatment with UFH/LMWH in patients who have received UFH in the prior 100 days or in whom such information cannot be obtained, assess the platelet count before starting UFH/LMWH and 24 hours afterwards. Assess the platelet count and compare it with previous results in every patient who develops fever, respiratory failure, heart failure, neurologic symptoms, or any other unexplained clinical symptoms within 30 minutes of the intravenous injection of UFH.
3. The course of HIT: After the discontinuation of heparin, the platelet count usually increases within a few days; serum antibodies against heparin-PF4 complexes remain elevated for several weeks or months. The most frequent cause of death in patients with HIT is pulmonary embolism, less commonly myocardial infarction or stroke.
4. Diagnosis: You may use the 4Ts pretest probability score (Table. Modified 4Ts pretest HIT probability...) to predict HIT. It should be suspected in patients after cardiac surgery and in those who have been treated with heparin (usually for ≥5 days) or have recently received heparin if the decrease in the platelet count is due to an unexplained cause. Another clinical sign that is associated with HIT is skin necrosis at the heparin injection sites. Do not delay appropriate treatment until the diagnosis is confirmed by laboratory test results (antiheparin antibodies). A useful indicator for the diagnosis is a characteristic increase in the platelet count observed after the discontinuation of heparin.
1) In the case of a strong suspicion of HIT based on clinical symptoms, immediately discontinue heparin (including flushing of intravenous catheters).
2) Continue anticoagulant treatment with one of the following drugs: bivalirudin, lepirudin, argatroban (which are administered intravenously); fondaparinux, usually 7.5 mg subcutaneously once daily; or a direct oral anticoagulant (DOAC), preferably oral rivaroxaban 15 mg bid for 21 days followed by 20 mg once daily thereafter.
3) If the patient is receiving a vitamin K antagonist (VKA) at the time of diagnosis of HIT, discontinue the VKA (the use of VKAs in the early phases of treatment of HIT complicated by deep vein thrombosis increases the risk of limb necrosis). Do not resume VKAs until the platelet count increases to >150,000/microL; start with a low dose (2-4 mg of acenocoumarol, 3-5 mg of warfarin) in combination with a nonheparin parenteral anticoagulant (preferably fondaparinux) that may be discontinued after 5 days if the platelet counts stabilize and the international normalized ratio has been maintained within the therapeutic range for 2 consecutive days. Alternatively, a DOAC (preferably rivaroxaban) can be administered alone.
4) In patients with no active bleeding, transfusion of platelet concentrates is not recommended.
6. Management of patients requiring cardiovascular surgery, cardiac catheterization, or percutaneous coronary intervention: In individuals with acute HIT or with a history of HIT (with no antibodies), replace heparin with one of the following anticoagulants: bivalirudin, argatroban, or lepirudin.
1. Osteopenia and osteoporosis: In patients treated for >3 months with UFH or (less commonly) LMWH, bone mineral density (BMD) usually decreases by a few percent (in rare cases a greater decrease is observed in patients treated with UFH). BMD usually returns to baseline values within a few months after the discontinuation of heparin. The risk increases with longer heparin administration (particularly >6 months) and with age.
2. Skin necrosis: This occurs rarely, usually after deep subcutaneous injections, typically in the abdominal wall.
3. Other: Allergic reactions (usually urticaria), hyperkalemia (inhibition of the aldosterone effect by UFH), headache, increase in serum aminotransferase levels, alopecia.
Only one option in each category may be selected
Thrombocytopenia: Compare the highest and the lowest platelet counts to calculate the % fall of platelet counts
– >50% fall in platelet counts and nadir ≥20,000/microL in a patient who has not undergone surgery within prior 3 days
– >50% fall in platelet counts and surgery within prior 3 days, or
– Any other combination of platelet count fall and nadir not fulfilling the other criteria
– <30% fall in platelet counts, or
– Any fall in platelet counts with a nadir <10,000/microL
Timing of the platelet count fall or thrombosis
– Onset within 5-10 days of starting heparin, or
– Onset within 1 day of starting heparin if heparin exposure within past 5-30 days
– Unconfirmed onset within 5-10 days of starting heparin (eg, some platelet count results are lacking)
– Onset within 1 day of starting heparin if heparin exposure within past 31-100 days
– Onset after day 10
Onset of thrombocytopenia within ≤4 days with no heparin exposure (day 0 is the first day of most recent exposure to heparin) within past 100 days
Thrombosis or other clinical sequelae
– Documented new thrombosis (arterial or venous)
– Skin necrosis at site of injection
– Anaphylactic reaction after IV heparin administration
– Adrenal hemorrhage
– Recurrent VTE in a patient treated with anticoagulants at therapeutic doses
– Documented thrombosis (still to be confirmed by imaging studies)
– Erythematous skin lesions at heparin injection sites
Other causes of thrombocytopenia not evident
No other evident causes for platelet count fall
Possible other causes are evident:
– Sepsis with no microbiologically confirmed etiologic factor
– Onset of thrombocytopenia associated with start of mechanical ventilation
Possible other causes:
– Within 72 h of a surgical procedure
– Documented bacteremia/fungemia
– Chemotherapy or radiotherapy within prior 20 days
– DIC caused by conditions other than HIT
– Posttransfusion thrombocytopenia
– Platelet count <20,000/microL in a patient who has received a drug known to cause immune thrombocytopeniaa
– Nonnecrotic skin lesions at LMWH injection sites (delayed hypersensitivity)
Pretest probability of HIT:
Score 6-8: High probability
Score 4-5: Intermediate probability
Score 0-3: Low probability
a Selected agents that may cause immune thrombocytopenia:
– Relatively frequently: GP II/IIIa antagonists (abciximab, eptifibatide, tirofiban), quinine, quinidine, sulfonamides, carbamazepine, vancomycin.
– Relatively infrequently: Actinomycin, amitriptyline, piperacillin, nafcillin, cephalosporins (cefazolin, ceftazidime, ceftriaxone), celecoxib, ciprofloxacin, esomeprazole, fexofenadine, fentanyl, fusidic acid, furosemide, gold salts, levofloxacin, metronidazole, naproxen, oxaliplatin, phenytoin, propranolol, propoxyphene, ranitidine, rifampin (INN rifampicin), suramin, trimethoprim.
DIC, disseminated intravascular coagulation; HIT, heparin-induced thrombocytopenia; INN, International Nonproprietary Name; IV, intravenous; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.